AMLX

Amylyx Pharmaceuticals (AMLX)

About Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Details

Daily high

$5.48

Daily low

$4.71

Price at open

$4.75

52 Week High

$7.27

52 Week Low

$1.58

Market cap

431.4M

Dividend yield

0.00%

Volume

2.0M

Avg. volume

1.0M

P/E ratio

-1.56

Amylyx Pharmaceuticals News